LongeVC Joins Rubedo Life Sciences’ $40M Series A Round To Pioneer Treatments for Biological Youth

As we age, the functionality of our cells decreases, leading to the accumulation of errors causing damage to cells over time. These errors are referred to as epigenetic changes, which ultimately result in the development of diseases in various organs and tissues. Senescent cells, which are responsible for age-related diseases, are among these pathological cells.

California-based Rubedo Life Sciences, a biopharmaceutical company developing a broad portfolio of innovative therapies targeting cells which drive chronic age-related diseases founded by Marco Quarta and Mark Gallop, has introduced the Alembic™ drug discovery platform, which allows them to identify specific potential targets for drugs and develop them into therapeutics that can selectively target pathological cells like senescent cells that cause aging. By addressing the root cause of age-related diseases, Rubedo has found a solid avenue to preserving biological youth.

We are happy to share that Rubedo Life Sciences has just announced that its $40M Series A round led by Khosla Ventures and Ahren Innovation Capital and joined by LongevC, Hevolution, R42, Modi Ventures, Cerigo Investments, Shanda Group, Refactor Capital and Italian Angels for Growth, among other investors.

Rubedo will use the funding to advance the company's lead candidate, a first-in-class therapy targeting senescent cells in chronic atopic dermatitis and chronic psoriasis. Rubedo is also developing additional therapies that selectively target senescent cells in pulmonary diseases with significant unmet medical needs, such as idiopathic pulmonary fibrosis (IPF), chronic liver diseases, neuromusculoskeletal diseases, and cancer.

Read more about Rubedo and its fundraise here. To learn more about Rubedo's multi-year partnership with Beiersdorf to pioneer new skin care products that address cellular aging, click here.